drugset / Trial / NCT01617070

Effects of Kuvan on Melatonin Secretion

NCT01617070

NaSingle-groupOpen-labelTreatment

Summary

This study examines the effect of tetrahydrobiopterin (Kuvan) and Large Neutral Amino Acid (LNAA) therapy on melatonin and dopamine levels in individuals with Phenylketonuria (PKU). The investigators hypothesize that Kuvan therapy will improve melatonin secretion and urine dopamine levels to some extent. However significantly greater responses in melatonin and dopamine secretions may be observed with combined treatment with Kuvan and supplementation of LNAA.

Timeline

Start
2012-05
Primary completion
2014-12
Completion
2014-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject sapropterin Unknown 20 mg/kg Oral

Indications